Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28148988 | 0.96 | — | — | |
| SCHEMBL6040938 | 0.88 | MEN1 (0.36) | MEN1KMT2ATSHRTHRBHTT | |
| SCHEMBL6040937 | 0.83 | MEN1 (0.48) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL20323857 | 0.83 | HSD17B10 (0.32) | MEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL22296974 | 0.83 | HSD17B10 (0.32) | MEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL7808059 | 0.82 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL3084586 | 0.82 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL7809339 | 0.82 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL7809336 | 0.82 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL9799369 | 0.79 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101522607-B | Preparation method of polyether amine | CLARIANT FINANCE BVI LTD | 2014-03-12 | — | — | CN | disclosed |
| US-8071814-B2 | Process for preparing polyetheramines | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-12-06 | — | — | US | disclosed |
| US-7696385-B2 | Polyetheramine production method | CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20100069671-A1 | Process For Preparing Polyetheramines | CLARIANT FINANCE (BVI) LIMITED (VG) | 2010-03-18 | — | — | US | disclosed |
| CN-101522607-A | Preparation method of polyether amine | CLARIANT INT LTD (VG) | 2009-09-02 | — | — | CN | disclosed |
| US-20090177013-A1 | Polyetheramine Production Method | CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) | 2009-07-09 | — | — | US | disclosed |
| CN-1732290-A | Hydrophobic-hydrophilic compounds for the treatment of metal surfaces | BASF AG (DE) | 2006-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090177013-A1 | Polyetheramine Production Method | PNMT, HRH3, HRH4 | MEN1 396/4885KMT2A 277/4885TSHR 404/4885 |
| US-20100069671-A1 | Process For Preparing Polyetheramines | OXER1, OXGR1, NR1H3 | MEN1 2890/4885KMT2A 1555/4885TSHR 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.